PMV Pharma finalizes $50.8 million offering, details rezatapopt data and NDA timeline

PMV Pharmaceuticals entered into a formal underwriting agreement on August 31, 2026 with TD Securities (USA) LLC, finalizing terms for its previously announced public offering. The deal covers 22,055,000 shares of common stock, pre-funded warrants to purchase 19,900,000 shares, and accompanying warrants to purchase 41,955,000 shares of common stock.¹

The combined public offering price was set at $1.21000 per share and accompanying warrant, or $1.20999 per pre-funded warrant and accompanying warrant, for total proceeds of $50,765,351, with underwriting discounts and commissions of $3,045,933 and proceeds before expenses of $47,719,418.² After the offering, 75,515,432 shares of common stock are expected to be outstanding, assuming no warrant exercises.²

As of June 30, 2026, PMV held cash, cash equivalents and restricted cash of $79.4 million.² The company said net proceeds from the offering, combined with existing cash, should fund operating expenses and capital expenditures into the first quarter of 2028.²

On the clinical side, the filing updates rezatapopt's progress in ovarian cancer. Among 76 patients in the Phase 2 efficacy population as of a May 14, 2026 data cutoff, the overall response rate was 46%, including four confirmed complete responses, 29 confirmed partial responses, and two unconfirmed partial responses.² Median time to response was 1.3 months, with a median duration of response of 10.0 months among confirmed responders.² Treatment-related adverse events were mostly Grade 1 and 2, with a 5% discontinuation rate due to such events.²

PMV said it plans to submit its NDA for platinum-resistant/refractory ovarian cancer with the TP53 Y220C mutation in the first quarter of 2027.²